TY - JOUR
T1 - Neurometabolite levels in antipsychotic-naïve/free patients with schizophrenia
T2 - A systematic review and meta-analysis of 1 H-MRS studies
AU - Iwata, Yusuke
AU - Nakajima, Shinichiro
AU - Plitman, Eric
AU - Mihashi, Yukiko
AU - Caravaggio, Fernando
AU - Chung, Jun Ku
AU - Kim, Julia
AU - Gerretsen, Philip
AU - Mimura, Masaru
AU - Remington, Gary
AU - Graff-Guerrero, Ariel
N1 - Funding Information:
YI has received fellowship grants from Canadian Institute of Health Research (CIHR), Keio University Medical Science Foundation, Mitsukoshi Foundation, Japan Foundation for Aging and Health, and manuscript fees from Dainippon Sumitomo Pharma. SN has received fellowship grants from CIHR and manuscript fees from Dainippon Sumitomo Pharma and Kyowa Hakko Kirin. EP has received research support from an Ontario Graduate Scholarship and a CIHR Canada Graduate Scholarship – Master's, and currently receives research support from a CIHR Vanier Canada Graduate Scholarship. FC has received fellowship grants from Ontario Graduate Scholarship (OGS). JC has received research support from a CIHR Canada Graduate Scholarship – Master's and currently receives research support from a CIHR Doctoral Award. PG has received fellowship awards from CIHR, OMHF and CAMH. MM has received grants and/or speaker's honoraria from Asahi Kasei Pharma, Astellas Pharmaceutical, Daiichi Sankyo, Dainippon-Sumitomo Pharma, Eisai, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutical, Meiji-Seika Pharma, Mochida Pharmaceutical, MSD, Novartis Pharma, Otsuka Pharmaceutical, Pfizer, Shionogi, Takeda, Tanabe Mitsubishi Pharma, and Yoshitomi Yakuhin within the past three years. GR has received external funding from CIHR, OMHF, and RHF-CFI, as well as consultant honoraria from Neurocrine Biosciences and Synchroneuron. AG has received research support from the following external funding agencies: the CIHR, US NIH, OMHF, NARSAD, Mexico Instituto de Ciencia y Tecnología del Distrito Federal, Consejo Nacional De Ciencia Y Tecnología, Ministry of Economic Development and Innovation of Ontario, Ontario AHSC AFP Innovation Fund and W. Garfield Weston Foundation. Other authors have no financial or other relationship relevant to the subject of this manuscript.
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2018/8/30
Y1 - 2018/8/30
N2 - Background: Studies using proton magnetic resonance spectroscopy ( 1 H-MRS) have reported altered neurometabolite levels in patients with schizophrenia. However, results are possibly confounded by the influence of antipsychotic (AP). Thus, this meta-analysis aimed to examine neurometabolite levels in AP-naïve/free patients with schizophrenia. Methods: A literature search was conducted using Embase, Medline, and PsycINFO to identify studies that compared neurometabolite levels in AP-naïve/free patients with schizophrenia to healthy controls (HCs). Eight neurometabolites (glutamate, glutamine, glutamate + glutamine, N-acetylaspartate [NAA], choline, creatine, myo-inositol, and γ-Aminobutyric acid [GABA]) and seven regions of interest (ROI; medial prefrontal cortex, dorsolateral prefrontal cortex, frontal white matter, occipital lobe, basal ganglia, hippocampus/medial temporal lobe, and thalamus) were examined. Results: Twenty-one studies (N = 1281) were included in the analysis. The results showed lower thalamic NAA levels (3 studies, n = 174, effect size = −0.56, P = 0.0005) in the patient group. No group differences were identified for other neurometabolites. Conclusions: Our findings suggest that impaired neuronal integrity in the thalamus may be a potential trait maker in the early stages of schizophrenia.
AB - Background: Studies using proton magnetic resonance spectroscopy ( 1 H-MRS) have reported altered neurometabolite levels in patients with schizophrenia. However, results are possibly confounded by the influence of antipsychotic (AP). Thus, this meta-analysis aimed to examine neurometabolite levels in AP-naïve/free patients with schizophrenia. Methods: A literature search was conducted using Embase, Medline, and PsycINFO to identify studies that compared neurometabolite levels in AP-naïve/free patients with schizophrenia to healthy controls (HCs). Eight neurometabolites (glutamate, glutamine, glutamate + glutamine, N-acetylaspartate [NAA], choline, creatine, myo-inositol, and γ-Aminobutyric acid [GABA]) and seven regions of interest (ROI; medial prefrontal cortex, dorsolateral prefrontal cortex, frontal white matter, occipital lobe, basal ganglia, hippocampus/medial temporal lobe, and thalamus) were examined. Results: Twenty-one studies (N = 1281) were included in the analysis. The results showed lower thalamic NAA levels (3 studies, n = 174, effect size = −0.56, P = 0.0005) in the patient group. No group differences were identified for other neurometabolites. Conclusions: Our findings suggest that impaired neuronal integrity in the thalamus may be a potential trait maker in the early stages of schizophrenia.
KW - Antipsychotic-naïve
KW - Proton magnetic resonance spectroscopy
KW - Schizophrenia
KW - Untreated
UR - http://www.scopus.com/inward/record.url?scp=85049051208&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049051208&partnerID=8YFLogxK
U2 - 10.1016/j.pnpbp.2018.03.016
DO - 10.1016/j.pnpbp.2018.03.016
M3 - Review article
C2 - 29580804
AN - SCOPUS:85049051208
SN - 0278-5846
VL - 86
SP - 340
EP - 352
JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry
JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry
ER -